NEW YORK, NY / ACCESSWIRE / January 31, 2019 / U.S. equities regained footing on Wednesday as investors cheered the latest round of corporate earnings and the Federal Reserve kept the interest rates unchanged at 2.25% to 2.50%. The Dow Jones Industrial Average went higher by 1.77 percent to close at 25,014.86, while the S&P 500 jumped 1.55 percent to settle at 2,681.05. The Nasdaq advanced 2.2 percent to close at 7,183.08.
According to the chief global market strategist at Invesco, Kristina Hooper, “More important than the Fed’s promise to be ‘patient’ about raising rates is the Fed’s assertion that it will not hesitate to make changes to balance sheet normalization. The balance sheet is a far more powerful tool, and one that has a bigger impact on the stock market.”
The Market Wealth Report Initiates Coverage on:
Alnylam Pharmaceuticals, Inc.
Sarepta Therapeutics, Inc.
Alnylam Pharmaceuticals' stock jumped 3.26% Wednesday, to close the day at $81.70. The stock recorded a trading volume of 463,099 shares, which was below its three months average volume of 946,439 shares. In the last year, Alnylam Pharmaceuticals' shares have traded in a range of 60.27 - 153.99. The share price has gained 35.56% from its 52 week low. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $76.87 is below its 200-day moving average of $86.76. Shares of Alnylam Pharmaceuticals have gained roughly 12.06 percent in the past month.
Access The Market Wealth's Alnylam Pharmaceuticals, Inc. Research Report:
On Wednesday, shares of Sarepta Therapeutics recorded a trading volume of 1,782,659 shares, which was above the three months average volume of 985,382 shares. The stock ended the day 12.19% higher at $129.93. The share price has fallen 26.39% from its 52 week high with a 52 week trading range of 50.68 - 176.50. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $114.14 is below its 200-day moving average of $128.51. Shares of Sarepta Therapeutics have gained roughly 19.06 percent in the past month.
Access The Market Wealth's Sarepta Therapeutics, Inc. Research Report:
The Market Wealth Report
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
The Market Wealth Report has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of MarketWealthReport.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. MarketWealthReport.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.marketwealthreport.com/disclaimer.
For any questions, inquiries, or comments reach out to us directly at:
The Market Wealth Report, Unit #901 511 Avenue of the Americas, New York, NY, 10011
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: The Market Wealth Report